Legal & General Group Plc - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 77 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Legal & General Group Plc ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$746,681
-39.2%
44,765
+0.6%
0.00%
Q2 2023$1,229,089
+179.3%
44,500
+132.5%
0.00%
Q1 2023$440,128
+180.0%
19,136
+32.8%
0.00%
Q4 2022$157,191
+40.3%
14,408
+8.4%
0.00%
Q3 2022$112,000
-21.7%
13,290
-26.7%
0.00%
Q2 2022$143,000
-72.0%
18,126
-16.1%
0.00%
Q1 2022$511,000
-29.7%
21,594
+1.6%
0.00%
Q4 2021$727,000
+99.2%
21,264
+3.1%
0.00%
Q3 2021$365,000
-35.2%
20,632
+64.3%
0.00%
Q2 2021$563,000
+106.2%
12,561
+19.1%
0.00%
Q1 2021$273,000
+31.2%
10,545
+2.3%
0.00%
Q4 2020$208,000
+193.0%
10,312
+185.2%
0.00%
Q3 2020$71,000
+7.6%
3,616
-2.8%
0.00%
Q2 2020$66,000
+247.4%
3,722
+38.4%
0.00%
Q1 2020$19,000
-24.0%
2,689
-23.4%
0.00%
Q4 2019$25,000
-32.4%
3,511
+13.8%
0.00%
Q3 2019$37,000
+19.4%
3,085
+21.9%
0.00%
Q2 2019$31,000
+63.2%
2,530
+14.7%
0.00%
Q1 2018$19,000
-58.7%
2,2050.0%0.00%
Q4 2017$46,000
+53.3%
2,205
+28.3%
0.00%
Q3 2017$30,000
+150.0%
1,718
+67.3%
0.00%
Q2 2017$12,000
-7.7%
1,0270.0%0.00%
Q1 2017$13,000
-56.7%
1,027
-23.5%
0.00%
Q4 2016$30,0001,3430.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q3 2019
NameSharesValueWeighting ↓
Pharmstandard International S.A. 750,632$7,724,00026.59%
BVF INC/IL 2,617,967$26,939,0002.37%
GREAT POINT PARTNERS LLC 982,449$10,109,0001.58%
Alambic Investment Management, L.P. 65,128$670,0000.53%
FARALLON CAPITAL MANAGEMENT LLC 2,243,202$23,083,0000.14%
ALGERT GLOBAL LLC 44,477$458,0000.10%
Monashee Investment Management LLC 42,945$442,0000.09%
Tekla Capital Management LLC 219,042$2,254,0000.08%
Spark Investment Management LLC 138,800$1,428,0000.08%
OXFORD ASSET MANAGEMENT LLP 187,653$1,904,0000.04%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders